Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a biotech filing packed with trial protocols, CCR4 pathway charts, and milestone clauses can drain hours. RAPT Therapeutics SEC filings explained simply turns that struggle into clarity. Whether you’re scanning how Phase 2 data shifts cash burn or checking royalty obligations, our platform surfaces what matters in seconds.
Stock Titan’s AI reads every RAPT Therapeutics annual report 10-K simplified, each RAPT Therapeutics quarterly earnings report 10-Q filing, and the swift RAPT Therapeutics 8-K material events explained, then highlights clinical results, liquidity updates, and risk factors in plain language. Need to follow executives? Get RAPT Therapeutics Form 4 insider transactions real-time alerts that detail every RAPT Therapeutics executive stock transactions Form 4. The same dashboard links you to the RAPT Therapeutics proxy statement executive compensation so you can see how option grants align with drug-development milestones.
Investors use these insights to:
- Gauge safety signals before capital raises with our RAPT Therapeutics earnings report filing analysis
- Track tranche payments tied to trial enrollment via automated 8-K summaries
- Spot trends in RAPT Therapeutics insider trading Form 4 transactions ahead of data readouts
RAPT Therapeutics, Inc. has a Schedule 13G disclosure showing Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, beneficially own 951,613 shares of RAPT common stock, representing 5.75% of the outstanding class. The filing states these shares are held by funds and separately managed accounts under Nantahala's control and that none of the Reporting Persons possess sole voting or dispositive power; all voting and dispositive power is shared. The statement affirms the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of the issuer.
RAPT Therapeutics, Inc. Schedule 13G/A filed by Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments III, L.P. reports beneficial ownership tied to both directly held common stock and exercisable warrants. Redmile Group and Mr. Green report 1,765,303 shares beneficially owned (9.9% of the class) and RBI III reports 1,147,390 shares (6.5% of the class). The filings explain ownership counts after a 1-for-8 reverse stock split and include up to 1,134,617 shares that could be issued upon exercise of certain pre-funded warrants subject to a 9.99% beneficial ownership blocker.
The filing discloses that Redmile Group acts as investment manager to Redmile Funds and that Mr. Green may be deemed to beneficially own the reported securities as principal of Redmile Group. Each reporting person disclaims beneficial ownership except for any pecuniary interest. The statement certifies the holdings are not for the purpose of changing control.
RAPT Therapeutics director Scott Braunstein received a stock option grant on June 21, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 25,000 stock options to purchase common stock
- Exercise price set at $7.43 per share
- Options expire on June 21, 2035
- Vesting schedule: Equal annual installments over three years from grant date
This equity compensation grant appears to be part of the company's standard director compensation program. The options were granted with direct ownership form, and the filing was submitted by attorney-in-fact Rodney Young on June 24, 2025. This transaction represents a new position for the director, as no prior holdings were reported in the filing.
RAPT Therapeutics has filed a Form 3 (Initial Statement of Beneficial Ownership) for newly appointed Director Scott Braunstein, effective June 21, 2025. The filing discloses that Mr. Braunstein currently holds no beneficial ownership of any securities in the company, either direct or indirect.
Key details from the filing:
- Position: Director (non-employee)
- Filing Status: Individual filing
- Business Address: 561 Eccles Avenue, South San Francisco, CA 94080
- No ownership of non-derivative securities reported
- No ownership of derivative securities (options, warrants, etc.) reported
The Form 3 was signed by Rodney Young as Attorney-in-Fact on June 24, 2025, fulfilling the SEC requirement for new insiders to report their initial securities ownership within 10 days of becoming an officer, director, or 10% owner.
RAPT Therapeutics Chief Medical Officer William Ho received a new stock option grant on June 20, 2025. The derivative securities transaction details include:
- Grant of 75,000 employee stock options
- Exercise price set at $7.43 per share
- Options expire on June 19, 2035
- Vesting schedule: 1/48th of shares vest monthly from June 20, 2025
This Form 4 filing, signed by attorney-in-fact Rodney Young, represents a standard equity compensation grant to a key executive officer. The ten-year option grant suggests a long-term retention strategy for the Chief Medical Officer position. The monthly vesting schedule over four years aligns with typical industry practices for executive compensation.
FAQ
What is the current stock price of Rapt Therapeutics (RAPT)?
What is the market cap of Rapt Therapeutics (RAPT)?
